CN111148502A - 具有两相体系的局部用产物 - Google Patents
具有两相体系的局部用产物 Download PDFInfo
- Publication number
- CN111148502A CN111148502A CN201880061003.2A CN201880061003A CN111148502A CN 111148502 A CN111148502 A CN 111148502A CN 201880061003 A CN201880061003 A CN 201880061003A CN 111148502 A CN111148502 A CN 111148502A
- Authority
- CN
- China
- Prior art keywords
- acid
- final concentration
- topical product
- product according
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940025703 topical product Drugs 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 35
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 26
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 13
- 229960004889 salicylic acid Drugs 0.000 claims description 13
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 12
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 229940099563 lactobionic acid Drugs 0.000 claims description 12
- 239000011975 tartaric acid Substances 0.000 claims description 12
- 235000002906 tartaric acid Nutrition 0.000 claims description 12
- 229960004106 citric acid Drugs 0.000 claims description 10
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 9
- 229960001367 tartaric acid Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229960004319 trichloroacetic acid Drugs 0.000 claims description 8
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 7
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 7
- 229960002887 deanol Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 150000001261 hydroxy acids Chemical class 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 6
- 229940088623 biologically active substance Drugs 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 5
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 5
- 235000019271 petrolatum Nutrition 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004264 Petrolatum Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 229940066842 petrolatum Drugs 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229920006317 cationic polymer Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 2
- 229960003681 gluconolactone Drugs 0.000 claims description 2
- 229960004275 glycolic acid Drugs 0.000 claims description 2
- 229960002591 hydroxyproline Drugs 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000006254 rheological additive Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 25
- 239000000126 substance Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 13
- 239000003381 stabilizer Substances 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 230000002051 biphasic effect Effects 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- -1 polysiloxane Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000010744 skin desquamation Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/03—Liquid compositions with two or more distinct layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
描述了一种两相局部用产物,包含亲水相和漂浮在所述亲水相上的亲脂相。还描述了一种制备两相局部用产物的方法。
Description
技术领域
本发明涉及具有两相体系的局部用产物,还涉及一种制备该局部用产物的方法。
背景技术
在医学和皮肤美容领域,在皮肤护理过程中,人们通常使用酸性物质来去除角质。这些护理方法称为化学换肤,是根据动词“剥脱”而来。它们的主要作用是唤醒肌肤活力,从而通过化学剥离来去除最表层皮肤,以促进肌肤再生。这种治疗方法能够通过不同机制的作用来作用于皮肤,其中不同机制的作用包括刺激细胞再生(转换),从而消除和去除角质层的死细胞。
随后,去除受损的或退化的细胞,这些受损或退化的细胞又会被表皮细胞替代。最常用于化学换肤的物质有:三氯乙酸、乙醇酸、间苯二酚、水杨酸、丙酮酸、苯酚、扁桃酸、乳酸、视黄酸、曲酸、柠檬酸、丙酮酸等。这些治疗取决于所用酸的类型,酸的浓度和化学稳定性以及涂抹区域。目前使用最广泛的物质之一是三氯乙酸,这是因为三氯乙酸的剥脱性最为突出。
从化学角度讲,它是一种羧酸,在室温下为无色结晶固体,具有刺激性,强吸湿性和高氧化性气味。三氯乙酸具有与乙酸类似的结构,其中三个氢原子已被三个氯原子取代。该取代将“α”碳的电子电荷移向氯原子,从而确定了上述碳上部分电子缺乏的状态,这又吸引了相邻碳的电子电荷,从而吸引了氧的电子电荷,如果将其引入水性环境中,由于负电荷的明显离域,其倾向于使质子更明显地分裂。
由于“β”中碳上三个氯原子产生的高负电势,分子的特定电子结构将电子平衡移向氯原子,并使分子的稳定性和可氧化性降低,从而促进了α碳和β碳之间的裂解,进而形成甲酸和氯仿等有害物质,这些有害物质对皮肤具有高度刺激性和致敏性。
三氯乙酸的氧化在医学领域是已知的,因为其涉及使包含三氯乙酸的产物褐变,通常以单相水凝胶的形式使用,并相对裂解三氯乙酸分子。化合物的褐变,除了会使产物的活性损失之外,还会使含三氯乙酸的产物的安全性大大损失,因为含三氯乙酸的产物将不再含有三氯乙酸本身,而是含有三氯乙酸、氯仿和甲酸的混合物。随着氧化过程的结束,混合物将趋于由后者组成,直到产物中所含的总三氯乙酸被分裂为止。
WO2007/042824A1描述了一种含有三氯乙酸、α-、β-和多羟基酸、维生素、氨基酸的组合物。所述组合物是油相的乳液,由聚硅氧烷、硅酮、矿物油或香精油组成。
US2009/0117068描述了一种适用于剃刀的固体组合物。所述组合物包含羟基酸、多羟基酸、三氯乙酸。
不利的是,所述化妆品组合物不能对三氯乙酸提供保护,三氯乙酸在与氧气接触时会氧化并改变其性质。
另一个缺点是由于目前没有一种系统允许在打开含有局部用组合物的包装之后还能够继续安全使用该局部用组合物。
US2014/037561描述了包含三氯乙酸的组合物,其用化学稳定剂的混合物以0.1∶1至5∶1的比例继续稳定。实施例5有提到,在相同条件下,在90天之后,虽然仅水溶液中的TCA降解了12.6%,但是在稳定剂百分比低的情况下,TCA平均降解了4-5%,而在稳定剂百分比高的情况下,TCA平均降解了2-3%。因此,该教导旨在相对于TCA增加化学稳定剂的量,但是没有提供关于90天后这种降解趋势的信息,并且当然没有考虑到组合物在皮肤上的耐受性的影响。
因此,本发明的目的是获得一种医用产物,特别是局部用产物,该产物能够使产物中存在的所有组分的性质随时间保持恒定。
另一个目的是获得能够保留三氯乙酸性质的局部用产物。
发明内容
根据本发明,这些目的通过如权利要求1所述的两相局部用产物来实现。
另一方面,本发明涉及一种制备局部用产物的方法,该局部用产物能够保留三氯乙酸的性质并防止其氧化,如权利要求22所述。
附图说明
通过以下具体实施方式,通过非限制性示例示出的实施例以及附图,本发明的特征和优点将变得更加明显,其中:
-图1示出了实施例1的两相产物。
具体实施方式
因此,本发明涉及一种两相局部用产物,其包含羟基酸、三氯乙酸和具有不剥落活性的生物活性物质的混合物,其中存在两个相,即,亲水相和亲脂相。由于所述亲脂相漂浮在亲水相上方,因此亲水相不与大气中存在的氧气直接接触。实际上,根据以下实施例和图1清晰所示,由于本发明的两相产物不含乳化表面活性剂,因此其在彼此互不相溶的两相之间具有或保持有清晰的分离表面。从这个意义上说,令人惊讶地发现,覆盖亲水相的亲脂相(其中存在三氯乙酸(或TCA))形成了隔离亲水相的物理屏障,从而防止了与空气的接触,因此,防止与氧气的接触,进而防止引起TCA的氧化。这允许克服与现有技术的乳液有关的缺点,该缺点会使含有TCA的相不可避免地暴露在空气中。
由此得出结论,TCA以及整个亲水相即使保存很长一段时间,甚至保存几年都不会发生明显变化,而且最重要的一点是未使用稳定剂或化学防腐剂。
实际上应该注意的是,从皮肤病学的角度来看,尽可能减少稳定剂和化学防腐剂的使用可确保产物更加天然和可耐受。但是,另一方面,由于没有稳定剂和化学防腐剂,天然产物本身比“化学”产物更精美,并且更易降解。
因此,本发明提供的解决方案是特别有利的,因为它不再需要用到稳定剂和化学防腐剂,同时产物的稳定性也不会受到损害,相反,随着时间的流逝获得了长久而恒定的保存能力。因此,本发明的两相产物既被皮肤高度耐受,即使在暴露于过敏的受试者的情况下,也极其稳定,并且在视觉上令人愉悦且具有商业吸引力。
因此,本发明的两相局部用产物包含羟基酸、三氯乙酸和具有不剥落活性的生物活性物质的混合物,其中所述局部用产物包含亲水相和亲脂相,该双两相局部用产物不含乳化表面活性剂,并且所述具有不剥落活性的生物活性物质包含维生素和氨基酸的混合物。
优选地,两相局部用产物也不含稳定剂和防腐剂。
羟基酸、三氯乙酸和生物活性物质的这种混合物存在于亲水相中。
所述羟基酸可以是α-羟基酸、β-羟基酸或多羟基酸。
α-羟基酸例如选自酒石酸、柠檬酸、乙醇酸、乳酸、苹果酸;β-羟基酸例如选自羟丁酸和水杨酸;多羟基酸例如选自乳糖酸和葡糖酸内酯。
亲水相优选包含酒石酸、柠檬酸、水杨酸和乳糖酸。
酒石酸的终浓度为2%至15%,优选为3%至12%,更优选为4%至10%。为了本发明的目的,“%”是指基于成分存在的相的重量的“wt%”。
柠檬酸的最终浓度为0.3wt%至5wt%,优选为0.4wt%至4wt%,更优选为0.5%至3%。
水杨酸的最终浓度为0.5wt%至14wt%,优选为0.75wt%至12wt%,更优选为1wt%至10wt%。
乳糖酸的终浓度为3wt%至10wt%,优选为4wt%至13wt%,更优选为5wt%至11wt%。
三氯乙酸的终浓度为5wt%至60wt%,优选为7wt%至55wt%,更优选为9wt%至50wt%。
亲水相中存在的氨基酸是例如甘氨酸、脯氨酸、羟脯氨酸和精氨酸。所述氨基酸的终浓度为0.01wt%至12wt%,优选为0.02wt%至10wt%,更优选为0.03wt%至10wt%。
亲水相中存在的维生素的终浓度为0.05wt%至2wt%,优选为0.06wt%至1.5wt%,更优选为0.07wt%至1wt%。
亲水相中存在的维生素是核黄素(维生素B2)和维生素C。
亲水相还包含具有收缩和肌肉松弛作用的γ-氨基丁酸(GABA)或二甲基氨基乙醇。
GABA的终浓度为1wt%至10wt%,优选为2wt%至8wt%,更优选为3wt%至7wt%。
二甲基氨基乙醇的终浓度为0.1wt%至1wt%,优选为0.2wt%至0.8wt%,更优选为0.3wt%至0.7wt%。
亲水相还可以包含添加剂、pH调节剂、润湿剂、流变改性剂,例如增粘剂和胶凝剂。例如,它可以包含阳离子聚合物,天然和半合成萃取的纤维素衍生物、二氧化硅及其衍生物、EDTA、磷酸氢钾和氢氧化钠。
所述亲水相还包含水。
局部用产物的亲脂相包含润湿剂和润肤剂以及重油和饱和石蜡烃的非均质混合物,例如凡士林油。
润肤剂和润湿剂可以选自肉豆蔻酸异丙酯和棕榈酸异丙酯,优选肉豆蔻酸异丙酯,其终浓度为30wt%至75wt%,优选为40wt%至70wt%。
凡士林油的最终浓度为20wt%至50wt%,优选为25wt%至45wt%,更优选为30wt%至40wt%。
在优选的实施例中,亲脂相包含凡士林油、肉豆蔻酸异丙酯、角鲨烷或其混合物,更优选其混合物。
本发明的两相局部用产物可以通过以下方法制备,该方法包括将各相的各个组分混合,然后将亲脂相随后添加到亲水相中。但是,已经开发出一种专门用于制备本发明产物的优选实施例的方法。
因此,本发明的第二方面包括一种制备用于局部使用,优选用于外部局部使用的产物的方法。
所述方法包括以下步骤:
-提供一定量的润湿剂和水;
-制备水杨酸、柠檬酸、酒石酸、乳糖酸和三氯乙酸的混合物;
-溶解其余组分;
-制备氢氧化钠溶液以调节上述混合物的pH;
-进行pH调节;
-提供足够量的亲脂性组分,应将其混合在一起;
-两相(分装/相加)是在包装时形成的,相继添加两相,首先是亲水相,然后是亲脂相。
所述方法优选包括以下步骤:
-提供一定量的润湿剂和水;
-制备混合物的步骤如下:先加入水杨酸,然后再按从浓度最小到浓度最大的顺序加入剩余的酸:柠檬酸、酒石酸、乳糖酸和三氯乙酸;
-制备氢氧化钠溶液以调节上述混合物的pH;
-调节pH值至多为1至2.5,公差为0.5;
-按照从浓度最小到浓度最大的顺序溶解其余组分;
-提供足够量的亲脂性组分,应将其混合在一起;
-两相是在包装时形成的,相继添加两相,首先是亲水相,然后是亲脂相。
如前所述,亲脂相的主要功能是保护三氯乙酸免于氧化,作为分配产物的最终瓶内存在的氧气的机械屏障。密闭瓶中与制剂接触的氧气将激活氧化过程,使三氯乙酸褐变(三氯乙酸裂解,本身不会变黑,但会分裂),三氯乙酸相对转化为降解产物,其对皮肤有害,且对皮肤具有高度刺激性和致敏性,例如氯仿和甲酸。
因此,在本发明中,亲脂相起到保护机构的作用,即使在亲水和亲脂相之间搅拌混合之后,也避免了包含三氯乙酸的亲水相与瓶中所含的氧气之间进行接触,这是因为亲脂相的微膜由于密度差异而始终保持在亲水相之上,因此永久性地保护该化合物不与氧气接触,从而防止三氯乙酸氧化,避免了三氯乙酸转化为对皮肤有害的物质。
这两个相可以具有两种不同的颜色,从商业角度和整体舒适性的角度来看,应使其具有更吸引人的颜色,例如,亲水相为黄色,亲脂相为蓝色。
亲脂相除了保护三氯乙酸之外,还具有第二功能,即,具有在皮肤上成膜,润肤和保湿的作用,这归功于优选通过以下成分获得的组合物:肉豆蔻酸异丙酯,其总用肉豆蔻的天然衍生物进行润湿和保湿;角鲨烷,具有皮肤保护功能,因为它具有再生脂质膜的能力,可防止外部因素的侵害,并具有保湿作用,可减少水从较深表皮层和凡士林油中的蒸发,从而形成保护膜(闭塞膜),能够减少表皮水分流失。
亲水相不仅以三氯乙酸为特征,而且优选以富含羟基的α(酒石酸、柠檬酸),β(水杨酸)和聚(乳糖酸)羟基酸的创新混合物为特征,该α羟基酸在本发明中被选有利地选择和按剂量分配,并且除了具有已知的去角质功能外,还具有附加的直接水合功能。此外,三氯乙酸和水杨酸的协同作用(称为角质剥脱剂)可渗透制剂中存在的氨基酸、维生素和生物活性物质。制剂中存在的氨基酸,优选甘氨酸、脯氨酸、羟脯氨酸、精氨酸、赖氨酸或其混合物,在胶原蛋白的合成中发挥刺激作用,是天然成分,并通过促进生物刺激过程而激活毛细血管微循环。
可以在这种治疗中首次引入氨基酸,有利地利用了氨基酸在酸性溶液中的等电平衡。维生素C作为催化剂,与氨基酸协同作用,催化新胶原蛋白的形成。亲水相还包含γ-氨基丁酸或二甲基氨基乙醇,具有收缩作用和肌肉松弛作用。
本发明最后涉及两相产物在皮肤的皮肤病学和皮肤美容治疗中,特别是在皮肤脱皮治疗中的局部,优选外部局部使用。
应该理解,两相产物的组分的优选方面,其制备及其用途的所有可能的组合均已被描述,因此是类似优选的。
还应该理解,被认为对于两相产物及其组分而言是优选和有利的所有方面也应被视为对于两相产物本身的制备和用途也同样是优选和有利的。
以下实施例是本发明的非限制性实施例。
实施例
实施例1
制备了根据本发明的两相局部用产物,其具有以下成分:
图1示出了所得的两相局部用产物。从图1中可清晰看到下面的亲水相和上面的亲脂相通过连续的分离表面而明显不同。
实施例2
制备了根据本发明的两相局部用产物,其具有以下成分:
实施例3
制备了根据本发明的两相局部用产物,其具有以下成分:
实施例4
稳定性评估
对实施例3中获得的产物进行测试,以验证其随时间变化的稳定性。
材料和方法
恒温控制器:
MEMMERT HPP260-Memmert GmbH+Co.KG
不受控制的室温(℃):5°<T<25°
受控的温度(℃):20°
受控的温度(℃):25°
pH计:
pH meter Basic 20-CRISON INSTRUMENT,SA
粘度计:
BROOKFIELD DV2T
微生物分析:
通过板夹物播种:
符合UNI EN ISO 21149:20170的需氧嗜常温菌计数CFU/G方法(简称“CBT”)
评估参数
时间对应:
·12周加速=1年
·24周加速=2年
以上结果清楚地表明,即使在加速老化的条件下,本发明产物在相当长的时间内,即,至多在长达2年内的稳定性都很高,不会出现明显变化。
Claims (23)
1.一种两相局部用产物,其包含羟基酸、三氯乙酸和具有不剥落活性的生物活性物质的混合物,其特征在于,所述两相局部用产物包含亲水相和漂浮在所述亲水相上的亲脂相,所述具有不剥落活性的生物活性物质包含维生素和氨基酸的混合物。
2.根据权利要求1所述的局部用产物,其特征在于,所述亲水相包含α-羟基酸、β-羟基酸或多羟基酸的混合物。
3.根据权利要求2所述的局部用产物,其特征在于,α-羟基酸选自酒石酸、柠檬酸、乙醇酸、乳酸、苹果酸;β-羟基酸选自羟丁酸和水杨酸;多羟基酸选自乳糖酸和葡糖酸内酯。
4.根据权利要求2和3所述的局部用产物,其特征在于,所述亲水相包含酒石酸、柠檬酸、水杨酸和乳糖酸。
5.根据前述权利要求中任一项所述的局部用产物,其特征在于,所述亲水相包含γ-氨基丁酸(GABA)或二甲基氨基乙醇。
6.根据前述权利要求中任一项所述的局部用产物,其特征在于,所述亲水相中存在的氨基酸选自甘氨酸、脯氨酸、羟脯氨酸、精氨酸和赖氨酸,维生素是核黄素和维生素C。
7.根据权利要求3和4所述的局部用产物,其特征在于,酒石酸的终浓度为2%至15%,柠檬酸的最终浓度为0.3wt%至5wt%,水杨酸的最终浓度为0.5wt%至14wt%,乳糖酸的终浓度为3wt%至10wt%,三氯乙酸的终浓度为5wt%至60wt%。
8.根据权利要求7所述的局部用产物,其特征在于,酒石酸的终浓度为3wt%至12wt%,柠檬酸的最终浓度为0.4wt%至4wt%,水杨酸的最终浓度为0.75wt%至12wt%,乳糖酸的终浓度为4wt%至13wt%,三氯乙酸的终浓度为7wt%至55wt%。
9.根据权利要求8所述的局部用产物,其特征在于,酒石酸的终浓度为4wt%至10wt%,柠檬酸的最终浓度为0.5wt%至3wt%,水杨酸的最终浓度为1wt%至10wt%,乳糖酸的终浓度为5wt%至11wt%,三氯乙酸的终浓度为9wt%至50wt%。
10.根据权利要求6所述的局部用产物,其特征在于,所述氨基酸的终浓度为0.01wt%至12wt%,维生素的终浓度为0.05wt%至2wt%。
11.根据权利要求10所述的局部用产物,其特征在于,所述氨基酸的终浓度为0.02wt%至10wt%,维生素的终浓度为0.06wt%至1.5wt%。
12.根据权利要求11所述的局部用产物,其特征在于,所述氨基酸的终浓度为0.03wt%至10wt%,维生素的终浓度为0.07wt%至1wt%。
13.根据权利要求5所述的局部用产物,其特征在于,GABA的终浓度为1wt%至10wt%,或者二甲基氨基乙醇的终浓度为0.1wt%至1wt%。
14.根据权利要求13所述的局部用产物,其特征在于,GABA的终浓度为2wt%至8wt%,或者二甲基氨基乙醇的终浓度为0.2wt%至0.8wt%。
15.根据权利要求14所述的局部用产物,其特征在于,GABA的终浓度为3wt%至7wt%,或者二甲基氨基乙醇的终浓度为0.3wt%至0.7wt%。
16.根据前述权利要求中任一项所述的局部用产物,其特征在于,所述亲水相包含添加剂、防腐剂、pH调节剂、润湿剂、流变改性剂,例如增粘剂和胶凝剂。
17.根据权利要求16所述的局部用产物,其特征在于,还包含阳离子聚合物,天然和半合成萃取的纤维素衍生物、二氧化硅及其衍生物、EDTA、磷酸氢钾、甘油、润湿剂和氢氧化钠。
18.根据前述权利要求中任一项所述的局部用产物,其特征在于,局部用产物的亲脂相包含润湿剂和润肤剂以及凡士林油。
19.根据权利要求18所述的局部用产物,其特征在于,所述润湿剂和润肤剂选自肉豆蔻酸异丙酯和棕榈酸异丙酯。
20.根据权利要求19所述的局部用产物,其特征在于,肉豆蔻酸异丙酯的终浓度为30%至75%,凡士林油的最终浓度为20%至50%。
21.根据权利要求20所述的局部用产物,其特征在于,肉豆蔻酸异丙酯的终浓度为40%至70%,凡士林油的最终浓度为25%至45%。
22.一种制备两相局部用产物的方法,其特征在于,包括以下步骤:
-提供润湿剂和水;
-制备水杨酸、柠檬酸、酒石酸、乳糖酸和三氯乙酸的混合物;
-制备氢氧化钠溶液以调节上述混合物的pH;
-调节所述混合物的pH;
-溶解其余组分;
-提供亲脂性组分,并将其混合在一起。
23.根据权利要求22所述的方法,其特征在于,还包括以下步骤:
-制备所述混合物的步骤如下:先加入水杨酸,然后再按从浓度最小到浓度最大的顺序加入剩余的酸:柠檬酸、酒石酸、乳糖酸和三氯乙酸;
-调节所述混合物的pH值至多为1至2.5,公差为0.5。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102017000104536A IT201700104536A1 (it) | 2017-09-19 | 2017-09-19 | Prodotti topici con sistema bifasico |
IT102017000104536 | 2017-09-19 | ||
PCT/IB2018/057131 WO2019058249A1 (en) | 2017-09-19 | 2018-09-18 | TOPICAL PRODUCTS WITH BIPHASIC SYSTEM |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111148502A true CN111148502A (zh) | 2020-05-12 |
CN111148502B CN111148502B (zh) | 2023-04-28 |
Family
ID=61006168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880061003.2A Active CN111148502B (zh) | 2017-09-19 | 2018-09-18 | 具有两相体系的局部用产物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US11504307B2 (zh) |
EP (1) | EP3694477B1 (zh) |
JP (1) | JP7135075B2 (zh) |
KR (1) | KR102706515B1 (zh) |
CN (1) | CN111148502B (zh) |
AU (1) | AU2018335555B2 (zh) |
BR (1) | BR112020005491B1 (zh) |
CA (1) | CA3073792A1 (zh) |
DK (1) | DK3694477T3 (zh) |
ES (1) | ES2905873T3 (zh) |
IT (1) | IT201700104536A1 (zh) |
MA (1) | MA50357A (zh) |
MX (1) | MX2020002957A (zh) |
PL (1) | PL3694477T3 (zh) |
PT (1) | PT3694477T (zh) |
RU (1) | RU2764769C2 (zh) |
WO (1) | WO2019058249A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700104536A1 (it) | 2017-09-19 | 2019-03-19 | Cmed Aesthetics Srl | Prodotti topici con sistema bifasico |
BR112021025249A2 (pt) * | 2019-06-24 | 2022-02-15 | Rossana Castellana | Formulações para uso odontológico e dermatológico que contêm sais de tricloroacetato e hidroxiácidos |
IT201900020526A1 (it) * | 2019-11-07 | 2021-05-07 | Francesco Leva | Formulazione trifasica emulsionabile e suoi impieghi terapeutici e/o cosmetologici |
WO2022131141A1 (en) * | 2020-12-14 | 2022-06-23 | L'oreal | Multi-phase composition comprising alpha hydroxy acid |
FR3118872B1 (fr) * | 2021-01-15 | 2024-02-02 | Oreal | Composition multiphasique comprenant un alpha-hydroxyacide |
FR3117834B1 (fr) * | 2020-12-17 | 2023-11-10 | Oreal | Composition cosmétique biphase comprenant un acide aminé et deux acides spécifiques |
AU2022274611A1 (en) | 2021-05-13 | 2023-11-16 | Colgate-Palmolive Company | Personal care formulations |
KR102648939B1 (ko) * | 2023-08-18 | 2024-03-19 | 한국콜마주식회사 | 산을 고함량으로 함유하는 화장료 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965145A (en) * | 1996-07-26 | 1999-10-12 | L'oreal | Use of honey as keratolytic agent for improving the radiance and the complexion of the skin and treating wrinkles |
JP2000186036A (ja) * | 1998-10-16 | 2000-07-04 | Showa Denko Kk | ケミカルピーリング剤組成物 |
EP1374831A1 (en) * | 2001-03-13 | 2004-01-02 | Ajinomoto Co., Inc. | Comsetics or external preparaiotns for skin |
US20140037561A1 (en) * | 2011-02-03 | 2014-02-06 | John E. Kulesza | Composition and methods of enhanced skin cell turnover |
CN103945838A (zh) * | 2011-09-23 | 2014-07-23 | 阿勒根公司 | 用于表皮剥脱的组合物及其用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU83173A1 (fr) * | 1981-02-27 | 1981-06-05 | Oreal | Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion |
DE4100490C1 (zh) | 1991-01-10 | 1992-03-05 | Goldwell Ag, 6100 Darmstadt, De | |
DE9320586U1 (de) | 1993-10-11 | 1994-10-13 | Hgb Pharma Service Gmbh | Topische Formulierung eines solubilisierten Ginkgo-biloba-Extraktes |
BR9803596A (pt) | 1997-09-23 | 2000-04-25 | Pfizer Prod Inc | Derivados do resorcinol. |
HN2000000033A (es) | 1999-03-22 | 2001-02-02 | Pfizer Prod Inc | Composicion de resorcinol |
WO2000069403A1 (en) * | 1999-05-18 | 2000-11-23 | Klein Marvin E | Alpha amino acid composition and method for the treatment of skin |
JP3970492B2 (ja) * | 1999-12-14 | 2007-09-05 | コスモ石油株式会社 | ピーリング用組成物 |
RU2195921C2 (ru) * | 2000-07-27 | 2003-01-10 | Научно-производственная фирма "Аквазинэль" | Крем от солнечных ожогов |
KR100858575B1 (ko) * | 2000-12-19 | 2008-09-17 | 가부시키가이샤 야쿠루트 혼샤 | 피부 외용제 및 그 제조 방법 |
US7477940B2 (en) * | 2003-06-30 | 2009-01-13 | J&J Consumer Companies, Inc. | Methods of administering an active agent to a human barrier membrane with galvanic generated electricity |
FR2859626B1 (fr) | 2003-09-12 | 2006-01-27 | Oreal | Composition biphase et ses utilisations dans le domaine cosmetique |
US7514092B2 (en) * | 2004-12-22 | 2009-04-07 | Avon Products, Inc. | Compositions and methods of their use for improving the condition and appearance of skin |
EP1937364A2 (en) | 2005-09-16 | 2008-07-02 | Reckitt Benckiser (UK) Limited | Improvements in or relatimg to cosmetic compositions |
GB0520931D0 (en) | 2005-10-14 | 2005-11-23 | Reckitt Benckiser Uk Ltd | Improvements in or relating to compositions |
ITUD20050211A1 (it) * | 2005-12-13 | 2007-06-14 | Rossana Castellana | Prodotto per il trattamento della pelle relativo procedimento di preparazione |
DE102006020382A1 (de) * | 2006-04-28 | 2007-10-31 | Henkel Kgaa | Schnell trocknende kosmetische Emulsionen zur Roll-on-Applikation |
FR2909279B1 (fr) * | 2006-11-30 | 2014-06-13 | Oreal | Procede de peeling a base de microgel cationique |
JP2008231010A (ja) * | 2007-03-20 | 2008-10-02 | Shiseido Co Ltd | 皮膚外用剤 |
GB2451224A (en) * | 2007-05-09 | 2009-01-28 | Frances Prenna Jones | Cosmetic composition comprising an exfoliant, astringent, antioxidant and moisturiser |
US8568749B2 (en) | 2009-04-02 | 2013-10-29 | Sesvalia Usa, Llc | Systems and methods for skin rejuvenation |
US8460687B1 (en) * | 2009-07-07 | 2013-06-11 | Cosmoceutical Research Center | Peeling compositions |
US8906432B2 (en) * | 2009-10-02 | 2014-12-09 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter |
DE102011110909A1 (de) * | 2011-08-18 | 2013-02-21 | Paul Hartmann Ag | Zusammensetzungen mit einer die Hautbarriere verbessernden Wirkstoffkombination |
WO2013091894A2 (en) * | 2011-12-21 | 2013-06-27 | Flavin Dana | Topical compositions |
PL224184B1 (pl) | 2012-02-22 | 2016-11-30 | Pulanna Spółka Z Ograniczoną Odpowiedzialnością | Naturalne kosmetyki wielofazowe |
MX2016014982A (es) | 2014-05-16 | 2017-03-31 | Restorsea Llc | Cosmetico bifasico. |
EP3006016A1 (en) * | 2014-10-06 | 2016-04-13 | Medical Brands Research B.V. | Dermatological kit comprising compositions based on Hibiscus flower and Buriti oil |
US20160250130A1 (en) * | 2014-12-18 | 2016-09-01 | The Ionto Team, S.L. | Cosmetic formulation and device for the treatment of deep wrinkles of the skin by means of iontophoresis |
IT201700104536A1 (it) | 2017-09-19 | 2019-03-19 | Cmed Aesthetics Srl | Prodotti topici con sistema bifasico |
-
2017
- 2017-09-19 IT IT102017000104536A patent/IT201700104536A1/it unknown
-
2018
- 2018-09-18 KR KR1020207011247A patent/KR102706515B1/ko active IP Right Grant
- 2018-09-18 RU RU2020113711A patent/RU2764769C2/ru active
- 2018-09-18 ES ES18786860T patent/ES2905873T3/es active Active
- 2018-09-18 BR BR112020005491-7A patent/BR112020005491B1/pt active IP Right Grant
- 2018-09-18 PT PT187868609T patent/PT3694477T/pt unknown
- 2018-09-18 CA CA3073792A patent/CA3073792A1/en active Pending
- 2018-09-18 JP JP2020515654A patent/JP7135075B2/ja active Active
- 2018-09-18 MX MX2020002957A patent/MX2020002957A/es unknown
- 2018-09-18 MA MA050357A patent/MA50357A/fr unknown
- 2018-09-18 US US16/644,975 patent/US11504307B2/en active Active
- 2018-09-18 EP EP18786860.9A patent/EP3694477B1/en active Active
- 2018-09-18 AU AU2018335555A patent/AU2018335555B2/en active Active
- 2018-09-18 CN CN201880061003.2A patent/CN111148502B/zh active Active
- 2018-09-18 WO PCT/IB2018/057131 patent/WO2019058249A1/en unknown
- 2018-09-18 PL PL18786860T patent/PL3694477T3/pl unknown
- 2018-09-18 DK DK18786860.9T patent/DK3694477T3/da active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965145A (en) * | 1996-07-26 | 1999-10-12 | L'oreal | Use of honey as keratolytic agent for improving the radiance and the complexion of the skin and treating wrinkles |
JP2000186036A (ja) * | 1998-10-16 | 2000-07-04 | Showa Denko Kk | ケミカルピーリング剤組成物 |
EP1374831A1 (en) * | 2001-03-13 | 2004-01-02 | Ajinomoto Co., Inc. | Comsetics or external preparaiotns for skin |
US20140037561A1 (en) * | 2011-02-03 | 2014-02-06 | John E. Kulesza | Composition and methods of enhanced skin cell turnover |
CN103945838A (zh) * | 2011-09-23 | 2014-07-23 | 阿勒根公司 | 用于表皮剥脱的组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
MA50357A (fr) | 2020-08-19 |
RU2764769C2 (ru) | 2022-01-21 |
KR102706515B1 (ko) | 2024-09-11 |
BR112020005491B1 (pt) | 2023-10-03 |
IT201700104536A1 (it) | 2019-03-19 |
EP3694477B1 (en) | 2021-12-01 |
ES2905873T3 (es) | 2022-04-12 |
AU2018335555A1 (en) | 2020-03-05 |
CN111148502B (zh) | 2023-04-28 |
JP2020534282A (ja) | 2020-11-26 |
DK3694477T3 (da) | 2022-03-07 |
PL3694477T3 (pl) | 2022-04-25 |
EP3694477A1 (en) | 2020-08-19 |
BR112020005491A2 (pt) | 2020-09-24 |
US11504307B2 (en) | 2022-11-22 |
KR20200055069A (ko) | 2020-05-20 |
US20200276090A1 (en) | 2020-09-03 |
JP7135075B2 (ja) | 2022-09-12 |
AU2018335555A9 (en) | 2023-09-07 |
WO2019058249A1 (en) | 2019-03-28 |
MX2020002957A (es) | 2022-05-26 |
RU2020113711A (ru) | 2021-10-20 |
AU2018335555B2 (en) | 2024-04-04 |
PT3694477T (pt) | 2022-02-08 |
CA3073792A1 (en) | 2019-03-28 |
RU2020113711A3 (zh) | 2021-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111148502A (zh) | 具有两相体系的局部用产物 | |
KR0178377B1 (ko) | 사용직전에혼합될수있는친수성담체및비타민c를갖는피부병리학적조성물 | |
DE60122312T2 (de) | Membranverabreichungssystem für wirkstoffe | |
JP3037145B2 (ja) | 水反応性活性剤を含むシリコーン組成物 | |
CN109846740B (zh) | 皮肤护理组合物及其制备方法和应用 | |
KR101189344B1 (ko) | 자가-보존성 스킨케어 조성물 | |
BRPI0500453B1 (pt) | Composição cosmética, método de intensificar a retenção de umidade na pele e método para inibir a taxa de perda de umidade da pele | |
CN111529438A (zh) | 一种虾青素抗氧化精华液及其制备方法 | |
CN111671716A (zh) | 一种抗氧化提亮肤色组合物及在化妆品中的应用 | |
US20180092816A1 (en) | Topical Hydrogen-Containing Skin Care Products | |
CN115137667A (zh) | 一种具有促渗功效的化妆品组合物及其应用 | |
US6239174B1 (en) | Emulsion containing ascorbic acid and its uses in the cosmetics and dermatological fields | |
JP4707437B2 (ja) | 天然保湿因子(nmf)成分産生促進剤 | |
US6465510B2 (en) | Emulsion containing ascorbic acid and its uses in the cosmetics and dermatological fields | |
CN116172895A (zh) | 化妆品组合物 | |
JP5986416B2 (ja) | 皮膚外用剤 | |
CN117295486A (zh) | 透明质酸盐的皮肤渗透用化妆料 | |
CN114569507A (zh) | 一种保湿乳液及其制备方法 | |
KR20090020407A (ko) | 나노리포좀 조성물 및 그로부터 제조된 나노리포좀을함유한 화장품 | |
JP2007022931A (ja) | 皮膚保護化粧料 | |
JP2004075635A (ja) | 保湿剤及び皮膚外用剤 | |
JP3333428B2 (ja) | 皮膚外用剤 | |
CN114533584B (zh) | 一种胶原蛋白酶抗皱面霜 | |
JP2000178118A (ja) | 保湿剤及び皮膚化粧料並びに入浴剤 | |
KR20070026906A (ko) | 알로에젤을 함유한 주름개선용 나노입자 조성물 및 그를함유한 화장료 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Pisa, Italy Patentee after: CMED Art Co.,Ltd. Country or region after: Italy Address before: Pisa, Italy Patentee before: CMED Art Co.,Ltd. Country or region before: Italy |